Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 11:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 7,077 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Cancer Clear all
Completed Phase 3 Interventional

Study to Evaluate SID 530 Compared to Taxotere

NCT00931008
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
SID530, Taxotere
Drug
Lead sponsor
SK Chemicals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Miami, Florida • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 28, 2026, 11:15 AM EDT
Completed Phase 1Phase 2 Interventional

Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver

NCT00041808
View directory record Official record
Conditions
Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Breast Neoplasms, Melanoma, Sarcoma, Gastrointestinal Neoplasms, Lung Neoplasms, Liver Neoplasms, Cholangiocarcinoma
Interventions
MTC-DOX for Injection, Chemotherapy
Drug · Procedure
Lead sponsor
FeRx
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
3
States / cities
San Diego, California • San Francisco, California • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 28, 2026, 11:15 AM EDT
Completed Not applicable Interventional

Enhancing Physical Activity Adherence After Breast Cancer Diagnosis (BEAT Cancer II)

NCT00929617
View directory record Official record
Conditions
Breast Cancer
Interventions
Experimental 1: exercise with 2 counseling types, Usual Care - written materials
Behavioral · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
3
States / cities
Birmingham, Alabama • Champaign, Illinois • Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Oct 28, 2026, 11:15 AM EDT
Recruiting No phase listed Observational

Multi-center MRD Registry for Inflammatory Breast Cancer

NCT06966050
View directory record Official record
Conditions
Breast Cancer
Interventions
Quality-of-life Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Timeline
2025 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 28, 2026, 11:15 AM EDT
Completed Phase 2 Interventional

Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2

NCT00005635
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, paclitaxel
Biological · Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Oct 28, 2026, 11:15 AM EDT
Completed Phase 2 Interventional Results available

Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer

NCT04294225
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Early-Stage Breast Carcinoma, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Anastrozole, Letrozole
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 28, 2026, 11:15 AM EDT
Completed Phase 3 Interventional

Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.

NCT00034125
View directory record Official record
Conditions
Breast Neoplasms
Interventions
LY353381, tamoxifen
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Miami, Florida • Shreveport, Louisiana • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2006 · Synced Oct 28, 2026, 11:15 AM EDT
Recruiting Phase 1 Interventional

First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

NCT05627960
View directory record Official record
Conditions
Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer, Non Small Cell Lung Cancer, Mesothelioma
Interventions
AG-01 Compound
Drug
Lead sponsor
A&G Pharmaceutical Inc.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Oct 28, 2026, 11:15 AM EDT
Terminated Phase 3 Interventional Results available

A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi

NCT01633060
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Fulvestrant, BKM120, BKM120 matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
37
States / cities
Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 28, 2026, 11:15 AM EDT
Completed Not applicable Interventional

Yoga for Aromatase Inhibitor-associated Joint Pain

NCT01951976
View directory record Official record
Conditions
Breast Cancer
Interventions
Questionnaires, Yoga Classes
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 28, 2026, 11:15 AM EDT
Recruiting No phase listed Observational

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer

NCT02610413
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2100
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 28, 2026, 11:15 AM EDT
Completed No phase listed Observational

Use of Molecular Breast Imaging (MBI) to Detect Additional Disease in Women With Breast Cancer Who Are About to go to Surgery

NCT00776308
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years and older · Female only
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2012 · Synced Oct 28, 2026, 11:15 AM EDT
Completed No phase listed Observational

Genetics and Heart Health After Cancer Therapy

NCT03510689
View directory record Official record
Conditions
Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, Brca2), Heart Diseases, Drug-Induced Cardiomyopathy
Interventions
echocardiography, Cardiopulmonary Exercise Testing, Blood Collection
Diagnostic Test · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 28, 2026, 11:15 AM EDT
Terminated Phase 1 Interventional

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

NCT03680560
View directory record Official record
Conditions
Solid Tumor, HER-2 Protein Overexpression
Interventions
ACTR T Cell Product, Trastuzumab
Biological · Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
New Haven, Connecticut • Miami, Florida • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 28, 2026, 11:15 AM EDT
Completed Not applicable Interventional

Paclitaxel and Radiation Therapy in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer

NCT00647218
View directory record Official record
Conditions
Breast Cancer
Interventions
Post-operative adjuvant therapy, neoadjuvant therapy, therapeutic surgical procedure, Radiation therapy with concurrent Paclitaxel, Hormonal Therapy
Drug · Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
6
States / cities
Frankling, Tennessee • Jackson, Tennessee • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 28, 2026, 11:15 AM EDT
Not listed Phase 1 Interventional

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

NCT05311618
View directory record Official record
Conditions
Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Endocervical Cancer, Squamous Cell Carcinoma of Head and Neck, Bladder Urothelial Cancer, Colorectal Cancer, Esophageal Cancer, Ovarian Cancer, Renal Cell Carcinoma, Prostate Cancer, Melanoma, Mesothelioma, Cholangiocarcinoma
Interventions
NGM438, Pembrolizumab (KEYTRUDA ®)
Drug
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Denver, Colorado • New Haven, Connecticut • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Oct 28, 2026, 11:15 AM EDT
Active, not recruiting Not applicable Interventional

The Genomic Medicine at VA Study

NCT04331535
View directory record Official record
Conditions
Coronary Artery Disease, Atrial Fibrillation, Type 2 Diabetes, Colorectal Cancer, Breast Cancer, Prostate Cancer
Interventions
Polygenic risk score (PRS)
Diagnostic Test
Lead sponsor
Boston VA Research Institute, Inc.
Other
Eligibility
50 Years to 70 Years
Enrollment
1,071 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 28, 2026, 11:15 AM EDT
Completed No phase listed Observational

Assessing Depression in a Geriatric Cancer Population

NCT00580476
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
70 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 28, 2026, 11:15 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

1380GCC: Prospective Study of GP-88 Blood Test in Healthy Women With Baseline Gail Model Risk Assessment Undergoing Screening for Breast Cancer

NCT02700776
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Phlebotomy - Blood sampling for GP88 at MM, SOC Tissue biopsy
Other · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
40 Years to 64 Years · Female only
Enrollment
417 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Glen Burnie, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Oct 28, 2026, 11:15 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer

NCT00195091
View directory record Official record
Conditions
Breast Cancer
Interventions
Tetrathiomolybdate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 28, 2026, 11:15 AM EDT
Completed Phase 2 Interventional Results available

Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer

NCT00082810
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
fulvestrant, tipifarnib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Oct 28, 2026, 11:15 AM EDT
Completed Phase 2 Interventional Results available

TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer

NCT03093350
View directory record Official record
Conditions
Breast Cancer
Interventions
TAA-specific CTLs
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 28, 2026, 11:15 AM EDT
Terminated Phase 1 Interventional

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

NCT05069935
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
FT538, Cyclophosphamide, Fludarabine, Monoclonal antibody - Dose Escalation, Monoclonal antibody - Dose Expansion
Drug · Combination Product
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Hackensack, New Jersey • Nashville, Tennessee • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 28, 2026, 11:15 AM EDT
Completed Phase 1 Interventional

A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors

NCT00465725
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastrointestinal Neoplasm, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer
Interventions
Picoplatin
Drug
Lead sponsor
Poniard Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Atlanta, Georgia • Las Vegas, Nevada • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Sep 24, 2009 · Synced Oct 28, 2026, 11:15 AM EDT